ISPOR 16th Annual International Meeting - Released Presentations
 

RELEASED PRESENTATIONS


PLENARY SESSIONS
 
FIRST PLENARY SESSION:
HEALTH CARE REFORM IN THE UNITED STATES - ONE YEAR LATER
 
The Affordable Care Act
Robert I. Field, JD, MPH, PhD,
Professor of Law, Earle Mack School of Law at Drexel University, Professor of Health Management and Policy, Drexel University School of Public Health, Philadelphia, PA, USA
 
U.S. Healthcare Reform: One Year Later
Allan M. Korn, MD
, Senior Vice President, Chief Medical Officer, Office of Clinical Affairs, Blue Cross and Blue Shield Association, Chicago, IL, USA
 
HRA and the Health Research Enterprise
Steve E. Phurrough, MD, MPA, Chief Operating Officer and Senior Clinical Director, Center for Medical Technology Policy, Baltimore, MD, USA

SECOND PLENARY SESSION:
Evolution of Comparative Effectiveness Research: Learning from the Past; Challenges for the Future
 
Comparative Effectiveness Research & The Patient-Centered Outcomes Research Institute
J. Sanford (Sandy) Schwartz, MD, Leon Hess Professor of Medicine, Health Care Management and Economics, The Wharton School, University of Pennsylvania, Philadelphia, PA, USA
 
Investments in Patient-Centered Outcomes Research
Carolyn M. Clancy, MD, Director, Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, Rockville, MD, USA
 
Conducting Comparative Effectiveness Research: The View of a Practicing Epidemiologist from the Other Washington
Bruce M. Psaty, MD, PhD,
Professor, Medicine, Epidemiology and Health Services, University of Washington and Investigator, Group Health Research Institute, Group Health Cooperative, Seattle, WA, USA

THIRD PLENARY SESSION:
MODELING GOOD RESEARCH PRACTICES – EVERYTHING YOU NEED TO KNOW
 
Modeling Task Force Recommendations
J. Jaime Caro, MDCM, FRCPC, FACP, Chair, ISPOR-SMDM Modeling Good Research Practices Task Force, and Senior Vice President, Health Economics, United BioSource Corporation, Lexington, MA, USA
 
Conceptualizing A Model: Questions You Should Be Asking
Mark Roberts MD, Chair, Conceptual Modeling and Data Source Preparation Working Group, and Professor and Chair, Department of Health Policy & Management, University of Pittsburgh, Pittsburgh, PA, USA
 
Addressing Uncertainty
Andrew Briggs, DPhil, Co-Chair, ISPOR-SMDM Modeling Good Research Practices Task Force, and Co-Chair, Model Parameter Estimation and Uncertainty Working Group, and Lindsay Chair in Health Policy & Economic Evaluation, Public Health & Health Policy, University of Glasgow, Glasgow, Scotland UK
 
Validation and Reporting
David Eddy PhD, MD, Co-Chair, Model Transparency and Validation Working Group, and Founder and Medical Director, Archimedes, Inc., San Francisco, CA USA
 
State Transition Models
Uwe Siebert, MD, MPH, MSc, ScD, Co-Chair, ISPOR-SMDM Modeling Good Research Practices Task Force, and Co-Chair, State-Transition Working Group, and Professor of Public Health, UMIT – Univ. of Health Sciences, Medical Informatics & Technology, Hall i.T, Austria
 
Discrete Event Simulation
Jonathan Karnon PhD, Co-Chair, Discrete Event Simulation Working Group, and Professor in Health Economics, University of Adelaide, Adelaide, South Australia
 
Dynamic Transmission Models
Richard Pitman PhD, Co-Chair, Dynamic Transmission Modeling Working Group, and, Senior Health Economist, Oxford Outcomes Ltd., Oxford, UK
 
PODIUM AND POSTER PRESENTATIONS
 

For contributed research podium and poster abstracts and released slide or poster presentations for the ISPOR 16th Annual International Meeting, see: ISPOR Outcomes Research Digest an electronic database of over 16,000 research papers presented at ISPOR Annual International Meetings, ISPOR Annual European Congresses, and biennial ISPOR Asia-Pacific & Latin America Conferences from 1998 to date.

  • ISPOR Outcomes Research Digest:  http://www.ispor.org/research_study_digest/research_index.asp
  • Under Meeting select 16th Annual International Meeting – Baltimore, MD, USA - 2011
  • Select Search for all research podium and poster abstracts and available slide or poster presentations from the meeting. Alternatively search by disease/disorder, topic or subtopic.

 WORKSHOP PRESENTATIONS

(Presentations to be added pending speaker approval)

 
W1: CONDUCTING & INTERPRETING INDIRECT TREATMENT COMPARISON AND NETWORK META-ANALYSIS: LEARNING THE BASICS

Indirect Treatment Comparisons and Network Meta-Analysis: The Concepts
Jeroen P. Jansen, PhD, MSc,
Research Director, Mapi Values, Boston

Indirect Treatment Comparisons and Network Meta-Analysis: Example
Neil Hawkins, PhD, Director, Oxford Outcomes Ltd, Oxford, UK

Indirect Treatment Comparisons and Network Meta-Analysis: Background
Joseph C. Cappelleri, PhD, MPH,
Pfizer Inc, New London, CT, USA

Indirect Treatment Comparisons and Network Meta-Analysis: Reporting and interpreting results
Rachael Fleurence, PhD, Director, Oxford Outcomes, Bethesda, MD, USA

 

W2: CHALLENGES AND SOLUTIONS IN CONDUCTING RETROSPECTIVE HEALTH ECONOMICS AND OUTCOMES RESEARCH STUDIES FOR ORPHAN DRUGS AND DISEASES

CHALLENGES
Zhimei Liu, PhD
, Associate Director, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

W4: CHOOSING PRO STATISTICAL ENDPOINTS TO MAXIMIZE SUCCESSFUL OUTCOMES

CHOOSING PRO STATISTICAL ENDPOINTS TO MAXIMIZE SUCCESSFUL OUTCOMES
Dennis D. Gagnon, MA, MABE, Senior Director, Strategic Consulting, Thomson Reuters, Santa Barbara, CA, USA

W5: USING CMS MEDICARE CLAIMS PUBLIC USE FILES (PUFS) FOR COMPARATIVE EFFECTIVENESS RESEARCH (CER)

Accessing CMS Claims Records: Data Enclave as a Virtual RDC
Elizabeth C. Hair, PhD, Senior Research Scientist, Public Health, NORC at the University of Chicago, Bethesda, MD, USA

Medicare Public Use Files for Comparative Effectiveness Research – Analysis of Relevant Laws and Regulations
Jane Hyatt Thorpe, JD, Associate Research Professor, Department of Health Policy, School of Public Health and Health Services, George Washington University Medical Center, Washington, DC, USA

CMS CER Public Use Data & Access Solution Pilot Project
Samuel C. "Chris" Haffer, PhD
, Program Manager - Information & Methods Group, Office of Research, Development, & Information, Centers for Medicare and Medicaid Services (CMS), Baltimore, MD, USA

W8: BRICS & MORTAR: BUILDING EMERGING MARKETS INTO GLOBAL HEOR PROGRAMS

BRICs & MORTAR: Building Emerging Markets into Global HEOR Programs
David Thompson, PhD
, Senior Vice President, Health Economics & Strategic Consulting, i3 Innovus, Medford, MA, USA

Industry Perspective: How Pharmaceutical Industry Adapt The Ever Changing Reimbursement Requirements-- China As An Example
Jianwei Xuan, PhD
, Senior Director/Team Leader, Pfizer, New York, NY, USA

W9: USING COMPARATIVE EFFECTIVENESS RESEARCH (CER) TO SUPPORT A VALUE BASED HEALTH CARE SYSTEM, EXAMPLES FROM THE UNITED STATES AND EUROPE

Using comparative effectiveness (CER) to support a value based health care (VBHC) system
Rachael Fleurence, PhD, Director, Oxford Outcomes, Bethesda, MD, USA

W10: DEVELOPING BETTER EVIDENCE OF PRODUCT SAFETY

Workshop Overview: Developing Better Evidence for Medical Product Safety
Joshua S. Benner, PharmD, ScD
, Research Director and Fellow, Engelberg Center for Health Care Reform, The Brookings Institution, Washington, DC, USA

FDA’s Mini‐Sentinel Program: Overview of Primary Data Resources and Distributed Data Approach
Jeffrey S. Brown, PhD
, Assistant Professor, Department of Population Medicine, Harvard Medical School, Harvard Pilgrim Health Care Institute, Boston, MA, USA

Update on FDA’s Sentinel Initiative
Judy Racoosin, MD, MPH
, Sentinel Initiative Scientific Lead, Office of Medical Policy, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

DEVELOPING BETTER EVIDENCE OF PRODUCT SAFETY
Paul Stang, PhD
, Senior Director of Epidemiology, Johnson & Johnson and Principal Investigator, Observational Medical Outcomes Partnership, Foundation for the National Institutes of Health, Philadelphia, PA, USA

W11: PATIENT PREFERENCES AND POLICIES: THE ROLE OF HEALTH-PREFERENCE DATA IN REGULATORY DECISION MAKING

PATIENT PREFERENCES AND POLICIES: THE ROLE OF HEALTH-PREFERENCE DATA
F. Reed Johnson, PhD, Distinguished Fellow and Principal Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA

W14: MICROECONOMIC TOOLS FOR UNDERSTANDING, MODELING, AND INFLUENCING HEALTHCARE DECISION MAKING

Microeconomic Modeling of Patient Decision Making
F. Reed Johnson, PhD, Distinguished Fellow and Principal Economist, Health Preference Assessment, RTI Health Solutions, Research Triangle Park, NC, USA

W15: PRACTICAL EXPERIENCES WITH THE USE OF BEST-WORST SCALING IN ECONOMIC EVALUATION

Practical Experiences with the Use of Best-Worst Scaling in Economic Evaluation
Terry Flynn, PhD, Head of Social Policy & Economic Evaluation, Centre for the Study of Choice (CenSoC), University of Technology, Sydney, Sydney, NSW, Australia

Practical Experiences with the Use of Best-Worst Scaling in Economic Evaluation
John F.P. Bridges, PhD
, Assistant Professor, Department of Health Policy and Management, Johns Hopkins Bloomsberg School of Public Health, Baltimore, MD, USA

Practical Experiences with the Use of Best-Worst Scaling in Economic Evaluation
Christine Poulos, PhD
, Senior Economist, Health Preference Assessment, RTI International, Research Triangle Park, NC, USA

W16: THE EVOLVING ROLE OF THE AGENCY FOR HEALTHCARE RESEARCH AND QUALITY (AHRQ) IN COMPARATIVE EFFECTIVENESS RESEARCH (CER)

The Evolving Role of AHRQ in Comparative Effectiveness Research
Jean Slutsky, PA, MSPH
, Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD, USA

W17: PATIENT-REPORTED OUTCOME (PRO) ASSESSMENTS IN CLINICAL TRIALS: NAVIGATING THE EMA AND FDA REGULATORY FRAMEWORK

A Comparison of Examples of EMA and FDA Disease Area Guidance Documents – Implications
Olivier Chassany, PhD, MD, Medical Manager, Department of Clinical Research and Development, Assistance Publique-Hopitaux de Paris, Paris, France

Patient-reported Outcome (PRO) Assessments in Clinical Trials: Navigating the EMA and FDA Regulatory Framework
Ingela Wiklund, PhD
, Senior Research Leader, Center for Health Outcomes Research, United BioSource Corporation, London, UK

Statistical Considerations and PRO Interpretation Comparisons
Kathleen W. Wyrwich, PhD
, Senior Research Leader, Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA

W20: STOCHASTIC MODELING IN PHARMACOECONOMICS – COMMON MISTAKES AND HOW TO AVOID THEM

STOCHASTIC MODELING IN PHARMACOECONOMICS: COMMON MISTAKES AND HOW TO AVOID THEM
Francisco J. Zagmutt, DVM, MPVM
, Managing Partner, EpiX Analytics, Boulder, CO, USA; Huybert Groenendaal, PhD, MSc, MBA, Managing Partner, EpiX Analytics, Boulder, CO, USA; Jane Castelli-Haley, MBA, Director, Health Economics & Outcomes Research, Teva Neuroscience, Inc., Kansas City, MO, USA

W22: ELECTRONIC HEALTH RECORDS AND MEANINGFUL USE: OPPORTUNITIES FOR EVOLUTION IN COMPARATIVE EFFECTIVENESS RESEARCH

The Role of CER in Health Care Reform
Eugene Rich, MD
, Senior Fellow and Director, Center on Health Care Effectiveness, Mathematica Policy Research, Washington, DC, DC, USA

The Next Transformation of CER through Electronic Health Records, Enhancing the Research Environment
Rolin Wade, RPh, MS
, Healthcare Executive and Principal Investigator, Cerner LifeSciences, Beverly Hills, CA, USA

W23: PRACTICAL APPROACHES FOR SYSTEMATIC ANALYSIS OF OBSERVATIONAL DATA; REAL WORLD CASE STUDIES FROM THE PHARMACEUTICAL INDUSTRY

Systematic Analysis - Incidence and Prevalence
David Miller, ScD, SM
, Director of Risk Management and Pharmacoepidemiology, Schwarz Bioscience Inc, Raleigh, NC, USA

PRACTICAL APPROACHES FOR SYSTEMATIC ANALYSIS
Jonathan A. Morris, MD
, Senior Vice President, United BioSource Corporation, Blue Bell, PA, USA

PRACTICAL APPROACHES FOR SYSTEMATIC ANALYSIS
Stephanie Reisinger
, Senior Director, United BioSource Corporation, Harrisburg, PA, USA

Practical Approaches for Systematic Analysis of Observational Data
Gregory E. Powell, PharmD, MBA
, Manager, GCSP, Research and Development, GlaxoSmithKline, Research Triangle Park, NC, USA

W27: PATIENT-CENTRIC OBSERVATIONAL RESEARCH: SUCCESSFULLY DESIGNING AND IMPLEMENTING STUDIES

PATIENT-CENTRIC OBSERVATIONAL RESEARCH: SUCCESSFULLY DESIGNING AND IMPLEMENTING STUDIES
Elisa Cascade, MBA, Vice President, MediGuard.org, Rockville, MD, USA

Case Study – How The Internet Enables Direct-To-Patient Research
Paul Wicks, PhD
, Research Director, PatientsLikeMe, Cambridge, MA, USA

W28: ADVANCED MISSING DATA TECHNIQUES IN OBSERVATIONAL RESEARCH: CASE STUDIES IN DATA LINKAGE AND IMPUTATIONS

Case 1: Imputation Techniques to Improve Data Availability from Electronic Medical Records
Alex K. Exuzides, PhD
, Director, Statistical Analysis, Lifecycle Sciences Group, ICON Clinical Research, San Francisco, CA, USA

 
ISSUE PANEL PRESENTATIONS

(Presentations to be added pending speaker approval)

 
IP1: IS FDA/CMS PARALLEL REVIEW WORTHWHILE? IS IT FEASIBLE?

IS FDA/CMS Parallel Review Worthwhile? Is it feasible?
Peter J Neumann, ScD, Professor and Director, The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA


IP2: PAYING FOR VALUE - WHICH TO GO FOR: THE NEW UK APPROACH OR THE NEW GERMAN LAW OR NEITHER?


IP3:  THE VALUE OF QALY:  IS THERE A SINGLE THRESHOLD VALUE OR DOES CONTEXT MATTER?

Assessments of Relative Efficacy: Do the Benefits Justify the Costs?
Benedikte Lensberg, MSc, Project Leader, i3 Innovus, Uxbridge, Middlesex, UK

Comparative efficacy: do the benefits justify the costs?
Kalipso Chalkidou, MD, Director, NICE International, National Institute for Health and Clinical Excellence, London, UK

Assessments of Relative Efficacy: Do the Benefits Justify the Costs?
Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK


IP4: WHAT CAN WE LEARN FROM SUCCESSES AND FAILURES IN PERSONALIZED MEDICINE? IMPLICATIONS FOR EVOLVING HEALTH ECONOMICS AND OUTCOMES RESEARCH PRACTICES

Overview of HTA and Reimbursement Recommendations on Personalized Medicine Products from North America, Europe and Australia. What are the Key Issues and Potential Lessons?
Eric Faulkner, MPH, Chair, ISPOR Personalized Medicine Reimbursement & Development Working Group, Senior Director, RTI Health Solutions, Executive Director, Genomics Biotech Emerging Medical Technology Institute, National Association of Managed Care Physicians, Assistant Professor, Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Research Triangle Park, NC USA

Successes and Failures in Personalized Medicine: The Role of Payors
Bruce Quinn, PhD, MD, Senior Health Policy Specialist, Foley Hoag, Boston, MA, USA

Responding to the Challenges of Personalized Medicine: Back to Basics - Again
Kostas Trakas, PhD, MSc, Senior Director, Worldwide Health Economics & Pricing, CNS, Johnson & Johnson Pharmaceutical Services LLC, Toronto, ON, Canada


IP5: DEBATING THE VALUE AND FUTURE DIRECTIONS OF PATIENT REGISTRIES IN COMPARATIVE EFFECTIVENESS RESEARCH

Debating the Value and Future Directions of Patient Registries in Comparative Effectiveness Research
Nancy Dreyer, PhD, MPH, Chief of Scientific Affairs, Senior Vice President, Outcome, Cambridge, MA, USA

Debating the value and future directions of patient registries in comparative effectiveness research
Robert McDonough MD, JD, MPP, Head, Clinical Policy Research and Development, Aetna, Hartford, CT, USA


IP6: WHEN IS THE EVIDENCE ADEQUATE? DIFFERENT PERSPECTIVES FROM KEY HEALTH CARE DECISION-MAKERS

When do we have enough evidence?
Bryan R. Luce, PhD, MBA, Senior Vice President, Science Policy, United BioSource Corporation, Bethesda, MD, USA

WHEN IS THE EVIDENCE ADEQUATE? DIFFERENT PERSPECTIVES FROM KEY HEALTH CARE DECISION‐MAKERS
Robert W. Dubois, MD, PhD, Chief Science Officer, National Pharmaceutical Council, Washington, DC, USA

How much evidence is adequate?
Steven Pearson, MD, MSc, President, Institute for Clinical and Economic Review, Boston, MA, USA


IP7: HOW DO WE STOP PAYING FOR LOW-VALUE CARE?

HOW DO WE STOP PAYING FOR LOW-VALUE CARE?
Sarah Garner, PhD
, Associate Director R&D NICE, Research and Development, NICE, London, UK

How Do We Stop Paying for Low-Value Care?
Peter J. Neumann, ScD, Professor and Director, The Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA

How do we stop paying for low-value care: Perspectives from initiatives in Australia
Adam Elshaug, MPH, PhD
, Harkness Fellow/Senior Research Fellow, School of Population Health and Clinical Practice, Adelaide University/AHRQ, Rockville, MD, USA


IP8: IDENTIFICATION, WEIGHTING AND PRIORITIZATION OF MULTIPLE ENDPOINTS FOR COMPARATIVE EFFECTIVENESS RESEARCH – WHAT HAVE WE LEARNED FROM GERMANY?

IDENTIFICATION, WEIGHTING AND PRIORITIZATION OF MULTIPLE ENDPOINTS FOR COMPARATIVE EFFECTIVENESS RESEARCH - WHAT HAVE WE LEARNED FROM GERMANY?
Michael Drummond, MCom, DPhil, Professor of Health Economics, Centre for Health Economics, University of York, Heslington, York, UK

Comparative Effectiveness Research and Benefit-Risk assessment. The case for AHP
Maarten J. IJzerman, PhD
, Professor & Chair, Department of Health Technology & Services Research, University Twente, Enschede, The Netherlands

Role of CA in HTA and CER: How IQWiG could use Conjoint Analysis
Axel Mühlbacher, PhD, Harkness Fellow in Health Care Policy and Practice, Duke Clinical Research Institute/ Fuqua School of Business, Duke University, Durham, NC, USA


IP9: WILL THE PROPOSED VALUE BASED PRICING WORK IN THE UK?

Value Based Pricing for drugs in the UK from 2014
Ron Akehurst, Professor of Health Economics, Dean of School of Health & Related Research, ScHARR, The University of Sheffield, Sheffield, UK

Will the Proposed Value-Based Pricing Work in the United Kingdom?
Stephen Beard, MSc, Head of Health Economics (Europe), RTI Health Solutions, Sheffield, UK

‘Value Based Pricing’ in the UK: Will it work?
Trevor Leighton, VP Pricing & Reimbursement, Shire AG, Eysins, Switzerland


IP10: HOW CAN PATIENT-REPORTED OUTCOMES BECOME A PART OF COMPARATIVE EFFECTIVENESS RESEARCH?


IP11: COVERAGE WITH EVIDENCE DEVELOPMENT IN THE PRIVATE INSURANCE SECTOR: IS IT A PIPEDREAM OR INEVITABLE FOR SOUND POLICY?

Coverage with Evidence Development (CED) in the private sector
Jens Grueger PhD, Vice President, Head Global Market Access Pfizer Ltd, London, UK

Coverage with Evidence Development in the Private Sector: Is It Necessary for Sound Policy or a Pipedream?
Penny Mohr, MA, Vice President, Program Development, Center for Medical Technology Policy, Baltimore, MD, USA

COVERAGE WITH EVIDENCE DEVELOPMENT IN THE PRIVATE INSURANCE SECTOR: IS IT A PIPEDREAM OR INEVITABLE FOR SOUND POLICY?
Seema Sonnad, PhD, Associate Professor, Department of Surgery, University of Pennsylvania, Philadelphia, PA, USA


IP12: EXPERIMENTAL VS. OBSERVATIONAL STUDIES: WHICH SHOULD HAVE A HIGHER RANK IN HEALTH CARE DECISIONS?

The Role of Observational Research in CER
Rachael Fleurence, PhD, Director, Oxford Outcomes, Bethesda, MD, USA

RCT vs. Observational Studies A View from a Healthplan
Winston Wong, PharmD, Associate Vice President, Pharmacy Management, CareFirst BlueCross BlueShield, Baltimore, MD, USA


IP13: ARE WE READY FOR A PRIME TIME TO CONDUCT RETROSPECTIVE COMPARATIVE EFFECTIVENESS STUDIES FOR ORPHAN DRUGS AND DISEASES

NOT–READY–VIEW
Zhimei Liu, PhD, Associate Director US Health Economics & Outcomes Research, Oncology Novartis Pharmaceutical Corporation, East Hanover, NJ, USA


IP14: WHO SHOULD FUND AND HAVE ACCESS TO SECONDARY DATA LINKAGES FOR ONCOLOGY OUTCOMES RESEARCH?

ISSUES, METHODS AND DIRECTIONS FOR FUTURE RESEARCH
Cathy J. Bradley, PhD, Professor, Department of Healthcare Policy and Research, Virginia Commonwealth University, Richmond, VA, USA

Multiple Examples of Recent (and Ongoing) Cancer Patterns-of-Care and Quality-of Care Studies Using Enhanced-Registry Data
Joseph Lipscomb, PhD, Professor, Department of Health Policy & Management, Emory University, Rollins School of Public Health, Atlanta, GA, USA

A COMMERCIAL AND INDUSTRY PERSPECTIVE
Kathleen Foley, PhD, Director, Strategic Consulting, Healthcare, Thomson Reuters, Cambridge, MA, USA


IP15: DO PATIENT-REPORTED OUTCOMES ADD VALUE IN HEALTH CARE DECISIONS?

Adding Value to Patient-Reported Outcomes: Providing a Theoretical Foundation
Andrea LaFountain, PhD, CEO, Mind Field Solutions Corp., Fairfax, VA, USA

Adding Value to Patient-Reported Outcomes: Enhancing Their Interpretation
Joseph C. Cappelleri, PhD, MPH, Senior Director, Biostatistics, Pfizer Inc., New London, CT, USA

Adding Value to Patient-Reported Outcomes: Applying PRO’s to Effective Communication
Mitch Golant, PhD, Senior Vice President, Research and Training, Cancer Support Community, Washington, DC, USA

ISPOR FORUMS
 

ISPOR Prospective Observational Clinical Studies Task Force
WHEN SEEING IS BELIEVING - COMPARATIVE EFFECTIVENESS: ISPOR GOOD RESEARCH PRACTICES ON PROSPECTIVE OBSERVATIONAL CLINICAL STUDIES

ISPOR Asia Consortium
PHARMACOECONOMIC GUIDELINES IN ASIA: FOCUS ON THE CHINA GUIDELINES FOR PHARMACOECONOMIC EVALUATIONS

ISPOR PRO Good Research Practices on Establishing and Reporting Evidence of Content Validity Task Force
CONTENT VALIDITY IN NEWLY DEVELOPED PATIENT REPORTED OUTCOMES INSTRUMENTS FOR MEDICAL PRODUCT EVALUATION: WHAT IS SUFFICIENT FOR REGULATORY SUBMISSIONS?

ISPOR HTA Special Interest Group
DEVELOPING EVIDENCE TO SUPPORT REIMBURSEMENT AND VALUE-BASED PRICING: ISSUES AND CHALLENGES FOR STAND-ALONE VERSUS COMPANION DIAGNOSTICS

ISPOR Russia Regional Chapter
RUSSIAN FEDERATION HEALTH CARE SYSTEM: ISSUES AND PROSPECTS

ISPOR Patient Reported Outcomes Special Interest Group & ISPOR PRO Task Forces
CONSIDERATIONS FOR USING MIXED MODES FOR PATIENT-REPORTED OUTCOMES DATA COLLECTION IN CLINICAL TRIALS AND VALIDATION OF COMPUTERIZED SYSTEMS TO CAPTURE OUTCOMES DATA

ISPOR Institutional Council
DIFFERENCES ON DIFFERENCES: DOES PERSPECTIVE MATTER WHEN CONSIDERING HETEREOGENEITY OF PATIENT TREATMENT EFFECTS

ISPOR Conjoint Analysis Experimental Design Task Force
DESIGNING CONJOINT EXPERIMENTS: A GUIDE TO ALTERNATIVE STRATEGIES

ISPOR Brazil Chapter
PHARMACOECONOMICS IN BRAZIL: REGULATORY TRENDS AND FUTURE PERSPECTIVES

ISPOR Poland, Greece and Serbia Regional Chapters
HEALTH TECHNOLOGY REIMBURSEMENT IN THE CEE REGION: EXPERIENCES OF COST CONTAINMENT MEASURES IN POLAND AND THE SOUTH CENTRAL EUROPEAN REGION

ISPOR Oncology SIG
A CHECKLIST FOR POPULATION SELECTION IN ONCOLOGY OUTCOMES RESEARCH USING RETROSPECTIVE DATABASES

Academy of Managed Care Pharmacy (AMCP) and ISPOR
Drug Information used in the Managed Care Pharmacy P&T Decision Making Process: Current Practice and Insights

 
EDUCATIONAL SYMPOSIA

(Presentations to be added pending symposia host approval)

 

TECHNOLOGY TRENDS IN GLOBAL PRICING AND MARKET ACCESS
(Sponsored by Adjility Health)

RCTs vs. OBSERVATIONAL STUDIES: THE NEXT GREAT DEBATE IN CER
(Sponsored by National Pharmaceutical Council )

CHALLENGES AND OPPORTUNITIES OF PROSPECTIVE OBSERVATIONAL RESEARCH
(Sponsored by PharmaNet Development Group )

NAVIGATING THE NEW COMPARATIVE EFFECTIVENESS LANDSCAPE: THE ROLE OF HEALTH INFORMATION TECHNOLOGY (HIT)
(Sponsored by United BioSource Corporation)

NEW PATIENT-LEVEL DATA FROM SENTINEL, ACA AND RECENT COMMERCIAL ENDEAVOURS: IMPLICATIONS FOR OUTCOMES RESEARCH
(Sponsored by IMS Consulting Group )
Register for Proceedings »

PHARMACEUTICAL BENEFIT-RISK ASSESSMENT – WHAT SHOULD WE DO IN THE ABSENCE OF REGULATORY GUIDANCE?
(Sponsored by RTI Health Solutions)

PERSONALIZED HEALTH CARE AND COMPARATIVE EFFECTIVENESS RESEARCH: REALIZING THE EVIDENCE ON “WHAT WORKS FOR WHOM AND WHEN”
(Sponsored by United BioSource Corporation )


16th Annual International Meeting Main Page